StockDuty ← Dashboard Aug 26, 2026 06:55 PM ET
SignalFDA/Bio

FDA APPROVES FIRST IN CLASS TARGETED THERAPY FOR METASTATIC PANCREATIC CANCER - HN

FDA approval of first-in-class targeted therapy marks major unmet need breakthrough.

FDA approval of first-in-class targeted therapy marks major unmet need breakthrough.
FDA approval of first-in-class targeted therapy marks major unmet need breakthrough. — impact context not separately stored; see What changed.
Sources